🇺🇸 SECLakefront Biotherapeutics NVDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 04:36:58·⟳ 抓取 04:37:21 +23s·⚡ 决策 10-14 04:38:58 +1m37s·13.6 天前
Lakefront Biotherapeutics披露既有回购计划上周回购126,322股，属例行执行无新增授权
这是外国发行人按监管要求提交的既有股票回购计划例行执行报告，不是新回购计划、额度上调、业绩/临床进展或并购信息；约332万欧元的周度回购金额相对上市公司通常仅具微小机械支撑，且执行窗口已经过去，没有可交易的预期差。
📄 原文Lakefront Biotherapeutics NV↗ 原文
----- f6k_101326.htm ----- 6-K 1 f6k_101326.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D…
不做 Lakefront Biotherapeutics NV（LKFT.US）
既有回购计划下的例行执行披露：126,322股、331.74万欧元已在10月5日至9日完成，本次无新增授权、额度变化或基本面信息，披露后缺乏可交易预期差。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Lakefront披露10月5日至9日在既有计划下回购126,322股、耗资约331.74万欧元。该事项为已发生的例行资本回报执行，无新增授权或基本面信息，不足以构成事件驱动交易。
关键理由
- 回购虽轻微利好每股权益，但本次仅为2026年6月9日既有计划的常规周度执行，新闻稿未给出新增授权、上限变化或加速回购安排。
- 126,322股、331.74万欧元的规模和已完成的10月5日至9日执行窗口，难以在披露后形成新的方向性重定价。
主要风险
- 若6月9日回购计划的总额度、剩余额度或同期临床/资本运作信息显著超出本次附件所述，可能改变资本配置判断；本6-K本身未披露这些增量。
- 纳斯达克与Euronext双重上市股份可能存在汇率、时区和流动性差异，但在无新增催化的情况下不影响回避结论。
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-10-13 · 影响 invalidates
未发现新增授权或基本面催化；披露仅为既有计划下10月5日至9日的小额回购执行，且回购窗口已经结束。
检索:检查6-K和Exhibit 99.1是否包含新增回购授权、额度上调、加速回购、注销安排、临床进展或指引上调 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不改变结论；核心决策依据是缺少新增事实和可交易预期差，因此直接AVOID。
方向:未使用先例：周度/阶段性回购执行明细通常只是既有计划的行政披露，方向上温和正面但不自动构成新催化。
涨幅量级:不适用：本次没有新授权、要约、注销或超额规模，且执行期已过，不能用新宣布回购计划的历史涨幅校准本次交易幅度。
形态:未检索可交易先例；即便其他公司新回购计划曾上涨，也不能外推到既有计划下约332万欧元的已完成周度执行。
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`lakefront biotherapeutics acquisition of own shares repurchase program june 9 2026 | lakefront biotherapeutics repurchase own shares october 2026 6-k | lkft share buyback 126,322 s`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen
原文全文
展开原文 · 6,737 字
----- f6k_101326.htm -----
6-K
1
f6k_101326.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number:
001-37384
Lakefront Biotherapeutics
(Translation of registrant's name into English)
Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).
On October 13, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c) Exhibit 99.1. Press release dated October 13, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Lakefront Biotherapeutics
(Registrant)
Date: October 13, 2026
/s/ Ying Deng
Ying Deng
Authorized Officer
----- exh_991.htm -----
EX-99.1
2
exh_991.htm
PRESS RELEASE
EdgarFiling
EXHIBIT 99.1
Acquisition of Own Shares
Mechelen, Belgium; October 13, 2026, 22.01 CET; regulated information
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext &
NASDAQ: LKFT) ("Lakefront") announces that between October 05, 2026 and October 09, 2026 it has repurchased 126,322 Lakefront shares via
a discretionary mandate to an independent financial intermediary, as follows:
Date
of purchase
Market/MTF
Number
of shares
Average
price paid (€)
Total
(€)
Lowest
price paid (€)
Highest
price paid (€)
10/5/2026
XAMS
20,641
26.14
539,466.98
25.78
26.50
10/5/2026
TQEX
442
26.01
11,497.92
25.90
26.04
10/5/2026
CEUX
2,656
25.97
68,975.52
25.82
26.22
10/5/2026
AQEU
174
25.88
4,503.12
25.88
25.88
10/6/2026
XAMS
20,421
26.40
539,130.74
25.94
26.64
10/6/2026
TQEX
1,383
26.54
36,708.97
26.20
26.64
10/6/2026
CEUX
2,620
26.51
69,458.30
26.42
26.64
10/6/2026
AQEU
679
26.59
18,051.55
26.44
26.64
10/7/2026
XAMS
22,325
26.15
583,776.43
25.86
26.54
10/7/2026
CEUX
2,566
26.16
67,136.05
25.90
26.48
10/7/2026
AQEU
506
26.18
13,246.17
26.00
26.50
10/8/2026
XAMS
22,557
26.20
591,027.24
25.82
26.78
10/8/2026
TQEX
150
26.27
3,940.01
26.24
26.34
10/8/2026
CEUX
2,158
26.27
56,690.44
26.20
26.36
10/8/2026
AQEU
817
26.20
21,408.91
26.20
26.22
10/9/2026
XAMS
21,498
26.40
567,643.94
26.18
26.66
10/9/2026
TQEX
592
26.38
15,616.60
26.34
26.46
10/9/2026
CEUX
3,394
26.37
89,516.07
26.34
26.44
10/9/2026
AQEU
743
26.40
19,612.97
26.34
26.46
Total
126,322
26.26
3,317,407.94
25.78
26.78
As of market close on October 9, 2026, Lakefront holds 1,877,353 of its own ordinary shares.
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building
a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage
portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell
engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront
identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term
shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1
412 522 6418
sherri.spear@lakefrontbio.com
Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com
Forward-looking statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but
are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are
based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements
may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity,
performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance,
financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those
risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”),
including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC.
Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such
forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking
statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking
statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.
6-K
1
f6k_101326.htm
FORM 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2026
Commission File Number:
001-37384
Lakefront Biotherapeutics
(Translation of registrant's name into English)
Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).
On October 13, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
(c) Exhibit 99.1. Press release dated October 13, 2026
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Lakefront Biotherapeutics
(Registrant)
Date: October 13, 2026
/s/ Ying Deng
Ying Deng
Authorized Officer
----- exh_991.htm -----
EX-99.1
2
exh_991.htm
PRESS RELEASE
EdgarFiling
EXHIBIT 99.1
Acquisition of Own Shares
Mechelen, Belgium; October 13, 2026, 22.01 CET; regulated information
Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext &
NASDAQ: LKFT) ("Lakefront") announces that between October 05, 2026 and October 09, 2026 it has repurchased 126,322 Lakefront shares via
a discretionary mandate to an independent financial intermediary, as follows:
Date
of purchase
Market/MTF
Number
of shares
Average
price paid (€)
Total
(€)
Lowest
price paid (€)
Highest
price paid (€)
10/5/2026
XAMS
20,641
26.14
539,466.98
25.78
26.50
10/5/2026
TQEX
442
26.01
11,497.92
25.90
26.04
10/5/2026
CEUX
2,656
25.97
68,975.52
25.82
26.22
10/5/2026
AQEU
174
25.88
4,503.12
25.88
25.88
10/6/2026
XAMS
20,421
26.40
539,130.74
25.94
26.64
10/6/2026
TQEX
1,383
26.54
36,708.97
26.20
26.64
10/6/2026
CEUX
2,620
26.51
69,458.30
26.42
26.64
10/6/2026
AQEU
679
26.59
18,051.55
26.44
26.64
10/7/2026
XAMS
22,325
26.15
583,776.43
25.86
26.54
10/7/2026
CEUX
2,566
26.16
67,136.05
25.90
26.48
10/7/2026
AQEU
506
26.18
13,246.17
26.00
26.50
10/8/2026
XAMS
22,557
26.20
591,027.24
25.82
26.78
10/8/2026
TQEX
150
26.27
3,940.01
26.24
26.34
10/8/2026
CEUX
2,158
26.27
56,690.44
26.20
26.36
10/8/2026
AQEU
817
26.20
21,408.91
26.20
26.22
10/9/2026
XAMS
21,498
26.40
567,643.94
26.18
26.66
10/9/2026
TQEX
592
26.38
15,616.60
26.34
26.46
10/9/2026
CEUX
3,394
26.37
89,516.07
26.34
26.44
10/9/2026
AQEU
743
26.40
19,612.97
26.34
26.46
Total
126,322
26.26
3,317,407.94
25.78
26.78
As of market close on October 9, 2026, Lakefront holds 1,877,353 of its own ordinary shares.
About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building
a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage
portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell
engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront
identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term
shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1
412 522 6418
sherri.spear@lakefrontbio.com
Richie Livingston
+1 312 636 7072
richie.livingston@lakefrontbio.com
Forward-looking statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but
are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,”
“intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,”
“will,” “could,” “would,” “potential,” “forward,” “goal,” “next,”
“continue,” “should,” “encouraging,” “aim,” “progress,” “remain,”
“explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements
regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are
based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements
may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity,
performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial
conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance,
financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those
risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”),
including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC.
Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition,
even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such
forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking
statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking
statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically
required by law or regulation.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
3d0ea00e48· 2026-10-14 04:38 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前